DIA-PSA – Anti-PSA (KLK3) (Hu) from Mouse (HAM18) – unconj. – 100 µl
antibody purified (from culture supernatant)
Prostate Specific Antigen
HAM18 has been developed for detection of prostate specific antigen (PSA) in routine formalin-fixed paraffin-embedded prostate tissue specimen to be used in bright field immunohistochemistry and for multicolor immunofluorescence. HAM18 has been tested for sensitivity, specificity and prognostic significance on more than 20.000 tissues. Accordingly, HAM18 stands for being the best validated anti-PSA clone.
Prostate Cancer is the most common cancer in men and PSA is the most important target for management of patients diagnosed with prostate cancer. PSA is a protease exclusively produced in prostate epithelial cells and secreted into the seminal fluid. Moreover, PSA reaches the blood stream and PSA levels have been shown to be proportional to quantity of prostate epithelial cells. Therefore serum analysis has developed the most commonly used method to detect PSA for prostate cancer prevention and to monitor response to therapy. Moreover, PSA immunohistochemistry is an important and common method for routine pathological diagnosis since it allows analysis of cellular expression profiles in prostate cancer.
In diagnostic routine, PSA (HAM18) immunohistochemistry can be used in the following applications
- Carcinoma of unknown origin: Rule out origin from a prostate cancer.
- Bladder tumor of male patients without unequivocal urothelial precursor lesion suggesting urothelial origin: Rule out origin from a prostate cancer.
- Advanced high-grade prostate cancer with rather low serum PSA levels: Low PSA expression in poorly differentiated cancer suggest that serum PSA levels may “underestimate” total tumor mass of the patient.
Immunohistochemistry of human PSA in routine formalin-fixed paraffin-embedded prostate cancer tissue with antibody clone HAM18
A: Strong apical predominance of PSA staining in a prostate cancer
B: Intense apical and cytoplasmic PSA staining in a prostate cancer
C: Loss of PSA staining pattern in a prostate cancer
D-F: Multiplex-IHC: Prostate gland – PSA (red), basal cells – p63 (white), epithelial cells – AE1-3 (green)
D: Normal prostate
E: Normal prostate, higher magnification
F: Prostate tumor: Absence of basal cells (white) in tumor tissue, but one normal gland displayed (white)
(pictures courtesy of Prof. Guido Sauter, Department of Pathology, University Hospital Eppendorf, Hamburg, Germany)
- Epstein JI et al. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol. 2014, 38: e6-e19
- Erbersdobler et al. Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. Urology 2009, 74(5): 1169-1173
- Wang W et al. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008. 32(1): 65-71.
- Yao JL et al. Small cell carcinoma of the prostate: an immunohistochemical study. Am J Surg Pathol. 2006, 30(6): 705-712.
- Goldstein NS et al. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol. 2002, 117(3): 471-477